| Document |
Document Title |
|
WO/2014/157380A1 |
Provided is a means whereby wounds or organ fibrosis can be easily treated within a short period of time. A therapeutic agent for wounds or fibrosis, said therapeutic agent comprising a substance capable of specifically inhibiting the ex...
|
|
WO/2014/157436A1 |
[Problem] The purpose of the present invention is to provide a formulation technique for improving the percutaneous absorption of diclofenac and/or a pharmaceutically acceptable salt thereof with respect to a pharmaceutical composition f...
|
|
WO/2014/157153A1 |
A muscle-atrophy-preventing agent containing as active ingredients a milk-derived basic protein fraction and/or a milk-derived basic protein fraction decomposition product. The muscle-atrophy-preventing agent has marked effects for preve...
|
|
WO/2014/160102A1 |
The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorde...
|
|
WO/2014/148455A1 |
Provided is a novel terpenoid derivative which exhibits anti-inflammatory action and cytoprotective action by activating Keap1/Nrf2/ARE signal transduction pathways. Terpenoid derivative A is represented by formula (1).
|
|
WO/2014/148646A1 |
The present invention addresses the problems of: providing a method for producing motor neurons from pluripotent stem cells quickly and in synchronisation, said motor neurons being satisfactorily provided with the properties of inherent ...
|
|
WO/2014/153172A1 |
Described herein are compounds of Formula (I-a) and (I-b), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT1 activity. Methods of using ...
|
|
WO/2014/148574A1 |
The purpose of the present invention is to find a substance capable of inhibiting the production of IL-2. The production of IL-2 can be inhibited with a compound represented by general formula (I) (wherein R1 to R4 and A are as defined i...
|
|
WO/2014/139318A1 |
An application of a phthalide compound in preparing a medicament. The medicament is specially used for promoting a stem cell to secrete one of the following items: telomerase, a neurotrophic factor (brain-derived neurotrophic factor, BDN...
|
|
WO/2014/144978A2 |
Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.
|
|
WO/2014/142276A1 |
The objective of the present invention is to provide a compound having a superior neurotrophic factor-like effect. The present invention provides a medicine containing the compound as the active ingredient. The present invention pertains...
|
|
WO/2014/145050A1 |
The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions...
|
|
WO/2014/123186A1 |
The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema3A protein participates, such as a neurode...
|
|
WO/2014/122604A1 |
Disclosed is an extract of Polygonum fagopyrum for use in the prevention or treatment of a condition, disorder or disease involving a reduction in the endogenous testosterone level in males.
|
|
WO/2014/118527A1 |
The present invention provides a topical composition comprising dantrolene and/or azumolene and one or more of a magnesium releasing compound and a compound which reacts with calcium ions under temperatures of 30 to 40 °C and pH levels ...
|
|
WO/2014/120654A1 |
The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2014/119634A1 |
The objective of the present invention is to develop and provide a novel muscle-building agent in which a muscle hypertrophy promoter and a muscle atrophy therapeutic agent are active ingredients, which can induce muscle building without...
|
|
WO/2014/119649A1 |
The objective of the present invention is to provide a compound, or a salt thereof, having regulatory activity on the function of lysophosphatidylserine receptors. The present invention provides a compound, or a salt thereof, having a ...
|
|
WO/2014/119753A1 |
[Problem] To provide a therapeutic drug that exhibits a strong, selective inhibitory activity against myostatin, and enables muscle hyperplasia and an increase in muscle mass. [Solution] A peptide selected from (a)-(d), below, or a pharm...
|
|
WO/2014/113878A1 |
A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic age...
|
|
WO/2014/113875A1 |
The present invention provides a method for the stimulation of secretion or expression of muscular IL-6 in a subject with the administration of Protectin DX (PDX). Particularly, the increase in circulating levels of IL-6 originating from...
|
|
WO/2014/113932A1 |
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I) or pharmaceutically acceptable salts thereof. (Formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compo...
|
|
WO/2014/116981A1 |
[0001] The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention inclu...
|
|
WO/2014/116845A1 |
The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2014/113784A1 |
The present invention relates to extracts of Sophora Flavascens, and compounds isolated therefrom for use in modulating airway smooth muscle contractility. Methods of creating enriched extracts of Sophora Flavascens are disclosed, as are...
|
|
WO/2014/111580A1 |
A composition comprising a sufficient amount of urolithin B or a derivative thereof, for increasing muscle cell size.
|
|
WO/2014/110291A1 |
Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and d...
|
|
WO/2014/107566A1 |
Microparticles and nanoparticles and compositions thereof are provided. The microparticles and nanoparticles and compositions may be used for the treatment of musculoskeletal disease, such as osteoarthritis and injury such as trauma.
|
|
WO/2014/106473A1 |
Disclosed is use of glycyrrhetinic acid or glycyrrhizic acid in preventing or treating radiation injury of soft tissue. Therefore, glycyrrhetinic acid or glycyrrhizic acid can be used for preparing medicaments for preventing or treating ...
|
|
WO/2014/103410A1 |
An IGF-1 production promoter comprises, as an active ingredient: a Citrus depressa Hayata extract, preferably water and/or organic solvent extract of Citrus depressa Hayata fruit or leaves, a supercritical extract of Citrus depressa Haya...
|
|
WO/2014/099904A1 |
Methods for enhancing motor function, enhancing functional status, and mitigating muscle weakness in a subject are provided. The methods utilize the combination of administering to the subject a nutritional composition comprising at leas...
|
|
WO/2014/098249A1 |
The purpose of the present invention is to provide a composition having a tissue repairing activity that is capable of promoting a reaction relating to tissue repairing. Disclosed is a composition having an activity of repairing a tissue...
|
|
WO/2014/089913A1 |
The present invention relates to a compound shown in a formula (I), a method for preparing the compound, a pharmaceutical composition containing the compound, and applications of the compound in preparing drugs for preventing and/or trea...
|
|
WO/2014/092150A1 |
A peptide or pharmaceutically acceptable salt thereof selected from the group consisting of Ala-Hyp-Gly, Hyp-Gly-Pro, Leu-Hyp, Glu-Hyp, Gly-Pro-Hyp, Pro-Ala, Hyp-Gly, and Pro-Hyp having more excellent myoblast differentiation acceleratio...
|
|
WO/2014/091446A1 |
The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
|
|
WO/2014/091020A1 |
The present invention refers to phenanthrene derivatives for use as medicaments, in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spin...
|
|
WO/2014/086687A1 |
The present invention relates to the use of CFTR correctors in the treatment of genetic disorders affecting striated muscle selected from sarcoglycanopathies, Brody's disease (BD) and the recessive forms of Cathecolaminergic Polymorphic ...
|
|
WO/2014/086243A1 |
Disclosed are a miRNA molecule for negatively regulating a type I interferon pathway and uses thereof, discovering that Has-miR-127-3p is closely related to systemic lupus erythematosus, and also verifying the target pathway of the miRNA...
|
|
WO/2014/088106A1 |
A substance capable of binding to mSin3B, said substance exhibiting an analgesic effect on an ICS (intermittent cold stress) mouse, which is an experimental animal model of fibromyalgia, and, therefore, being useful as a prophylactic or ...
|
|
WO/2014/087298A1 |
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or –CR0 --, where R0 is hydrogen, C1 -C6 linear or branched chain alkyl, etc., Z is –CRe --, or, –N--, where Re is hydrogen, C1 -C6 linear or branched...
|
|
WO/2014/084434A1 |
To prevent and treat a rotator cuff injury, the present invention provides a composition for preventing and treating a rotator cuff injury, containing cyanidin or delphinidin as an active ingredient.
|
|
WO/2014/075135A1 |
The present invention relates to pharmaceutical compositions formulated for transmucosal delivery, and in particular sublingual delivery, comprising at least one tocotrienol or derivative thereof together with one or more pharmaceuticall...
|
|
WO/2014/066964A1 |
The present Certificate of Addition relates to the use of pharmaceutical compositions containing a Mas receptor agonist, such as Angiotensin-(1-7), for treating degenerative muscular diseases.
|
|
WO/2014/071131A1 |
The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1.
|
|
WO/2014/065413A1 |
A compound represented by general formula [I] or a pharmaceutically acceptable salt thereof. (In the formula, each symbol is as defined in the description.)
|
|
WO/2014/065341A1 |
The present invent addresses the problem of providing a medicine for treating amyotrophic lateral sclerosis, a disease for which there is currently no effective therapeutic agent, and provides a therapeutic agent for amyotrophic lateral ...
|
|
WO/2014/063602A1 |
Disclosed is a drug targeting delivery adjuvant, which is at least one selected from the group of pentoses selected from xylose and arabinose; hexoses selected from glucose, galactose, fructose and mannose; sugar alcohols selected from s...
|
|
WO/2014/058000A1 |
The purpose of the present invention is to provide a 5-HT2B receptor antagonist which does not induce problematic adverse side effects or the like and can be used safely. Provided are a serotonin 2B receptor antagonist and a prophylactic...
|
|
WO/2014/059013A1 |
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e...
|
|
WO/2014/059403A1 |
Described herein are chimeric proteins, pharmaceutical compositions and methods for treating organophosphate exposure and poisoning (e.g., nerve agent poisoning, pesticide poisoning) in a subject (e.g., a human subject) and preventing or...
|
